Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: URN009
MIFTS: 49

Urinary System Disease

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Urinary System Disease

About this section

MalaCards integrated aliases for Urinary System Disease:

Name: Urinary System Disease 12 15
Abnormality of the Urinary System 29 6
Congenital Malformation of the Urinary System 73
Non-Neoplastic Urinary System Disorder 73
Non-Neoplastic Urinary Tract Disease 12
Urinary Tract Diseases 55
Urinary Tract Disease 12
Urinary Tract Anomaly 55
Urologic Diseases 73

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:18
NCIt 50 C27599
ICD10 33 N39 N39.8
Sources

Summaries for Urinary System Disease

About this section
Disease Ontology : 12 A disease of anatomical entity that is located in kidney, ureter, bladder and urethra.

MalaCards based summary : Urinary System Disease, also known as abnormality of the urinary system, is related to bladder disease and kidney disease, and has symptoms including dysuria, polyuria and renal colic. An important gene associated with Urinary System Disease is B2M (Beta-2-Microglobulin), and among its related pathways/superpathways are Primary Focal Segmental Glomerulosclerosis FSGS and Osteoblast Signaling. The drugs leucovorin and Cranberry have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and skin, and related phenotypes are cardiovascular system and homeostasis/metabolism

Sources

Related Diseases for Urinary System Disease

About this section

Diseases related to Urinary System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Related Disease Score Top Affiliating Genes
1 bladder disease 31.9 CRP KLK3 KRT20 TRPV1
2 kidney disease 31.3 ACE ALB B2M CRP CST3 EPO
3 vesicoureteral reflux 1 30.5 CRP NAGLU REN UMOD
4 acute pyelonephritis 30.3 ALB CRP NAGLU
5 pyuria 30.2 ALB CRP
6 pyelonephritis 30.2 ACE ALB CRP NAGLU UMOD
7 cystitis 30.1 CRP KRT20 TRPV1 UMOD
8 acute cystitis 30.1 ALB CRP KLK3 LCN2
9 chronic kidney failure 29.6 ACE ALB B2M CRP CST3 EPO
10 congenital anomalies of kidney and urinary tract 2 11.6
11 congenital anomalies of kidney and urinary tract 1 11.3
12 exstrophy of bladder 11.0
13 chromosome 6q11-q14 deletion syndrome 11.0
14 alpha-thalassemia 10.9
15 cakut 10.9
16 urethral syndrome 10.9
17 bacteriuria 10.9
18 ureteral disease 10.9
19 lower urinary tract calculus 10.9
20 loeffler syndrome 10.4 ACE ALB
21 hyporeninemic hypoaldosteronism 10.4 ACE REN
22 hypoaldosteronism 10.4 ACE REN
23 meningoencephalitis 10.4 ALB B2M TLR9
24 uremic neuropathy 10.4 B2M EPO PTH
25 anuria 10.4 ACE ALB REN
26 hypertensive nephropathy 10.4 ACE ALB NAGLU
27 prostatic acinar adenocarcinoma 10.4 KLK3 KRT20 WT1
28 cystic kidney disease 10.4 ALB B2M TRPV1 UMOD
29 pyelitis 10.4 B2M CRP REN
30 microvascular complications of diabetes 3 10.4 ACE ALB NPHS1
31 hypertensive encephalopathy 10.4 ACE EPO REN
32 renal artery disease 10.4 ACE EPO REN
33 renal tuberculosis 10.4 B2M CRP REN
34 hypersensitivity reaction type iii disease 10.4 ALB CRP TLR9
35 hydronephrosis 10.4 ALB B2M NAGLU
36 hyperparathyroidism 10.4 EPO FGF23 PTH
37 kidney hypertrophy 10.4 ALB NPHS1 NPHS2
38 hemorrhagic fever with renal syndrome 10.4 ALB B2M CRP
39 angiokeratoma of fordyce 10.4 ACE WT1
40 orthostatic proteinuria 10.4 ACE ALB B2M REN
41 renal artery obstruction 10.4 ACE REN
42 atrial septal defect 3 10.4 NPHS1 NPHS2 REN
43 immunodeficiency 43 10.4 ALB B2M
44 pure autonomic failure 10.4 ACE EPO REN
45 extrinsic cardiomyopathy 10.4 ACE CRP TLR9
46 seminal vesicle adenocarcinoma 10.4 KLK3 KRT20
47 parathyroid gland disease 10.4 ALB FGF23 PTH
48 obstructive nephropathy 10.4 ACE ALB REN
49 nephrotic syndrome, type 6 10.4 NPHS1 NPHS2 WT1
50 upper respiratory tract disease 10.4 ALB TLR9 TRPV1

Graphical network of the top 20 diseases related to Urinary System Disease:



Diseases related to Urinary System Disease
Sources

Symptoms & Phenotypes for Urinary System Disease

About this section

UMLS symptoms related to Urinary System Disease:


dysuria, polyuria, renal colic, urgency of micturition, other and unspecified genitourinary symptoms, pain in urethra, uti symptoms, urethral burning on micturition, loin pain, ureteral pain, flank tenderness, difficulty passing urine, urinary tenesmus, burning urination, bladder discomfort, renal pain, urologic problem

MGI Mouse Phenotypes related to Urinary System Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.32 ACE B2M CRP CST3 EPO FGF23
2 homeostasis/metabolism MP:0005376 10.27 ACE ALB B2M CRP CST3 EPO
3 growth/size/body region MP:0005378 10.21 ACE B2M FGF23 LCN2 NAGLU NPHS2
4 cellular MP:0005384 10.2 ALB B2M EPO LCN2 NAGLU PTH
5 immune system MP:0005387 10.17 ACE B2M CRP EPO FGF23 LCN2
6 hematopoietic system MP:0005397 10.14 ACE B2M EPO FGF23 LCN2 NAGLU
7 mortality/aging MP:0010768 10.03 ACE ALB B2M CST3 EPO FGF23
8 liver/biliary system MP:0005370 9.86 ACE ALB B2M EPO LCN2 NAGLU
9 renal/urinary system MP:0005367 9.44 ACE ALB FGF23 LCN2 NAGLU NPHS1
10 neoplasm MP:0002006 9.43 ACE ALB B2M CST3 TRPV1 WT1
Sources

Drugs & Therapeutics for Urinary System Disease

About this section

Drugs for Urinary System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1546)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
2 Cranberry Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
3
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 738-70-5 5578
4
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 67-20-9 5353830
5
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 104987-11-3 445643 439492
6
Ofloxacin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 82419-36-1 4583
7
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 100986-85-4 149096
8
Pitavastatin Approved Phase 4,Phase 1 147511-69-1, 147526-32-7 5282452 6366718
9
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 6493-05-6 4740
10
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 138402-11-6 3749
11
Telmisartan Approved, Investigational Phase 4,Phase 3,Not Applicable 144701-48-4 65999
12
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145040-37-5 2540
13
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
14
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137862-53-4 60846
15
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144689-63-4, 144689-24-7 158781 130881
16
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114798-26-4 3961
17
Everolimus Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 159351-69-6 6442177
18
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616
19
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
20
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 616-91-1 12035
21
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 24280-93-1 446541
22
alemtuzumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216503-57-0
23
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75847-73-3 5362032 40466924
24
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76420-72-9 6917719
25
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6 23925
26
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 76-42-6 5284603
27
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
28
Sulbactam Approved Phase 4,Phase 3,Phase 2,Phase 1 68373-14-8
29
Piperacillin Approved Phase 4,Phase 2,Phase 3 66258-76-2 43672
30
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6 772 46507594
31
Dalteparin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9005-49-6
32
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 2,Not Applicable 9004-61-9 53477741
33
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 54-31-9 3440
34
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
35
Spironolactone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 52-01-7, 1952-01-7 5833
36
Warfarin Approved Phase 4,Phase 3,Phase 2,Phase 1 81-81-2 6691 54678486
37
Amiodarone Approved, Investigational Phase 4,Not Applicable 1951-25-3 2157
38
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Not Applicable 128-13-2 31401
39
Digoxin Approved Phase 4 20830-75-5 30322 2724385
40
Pirfenidone Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53179-13-8 40632
41
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 113775-47-6 68602 5311068
42
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
43 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44
acetic acid Approved Phase 4,Not Applicable 64-19-7 176
45
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
46
Progesterone Approved, Vet_approved Phase 4,Not Applicable 57-83-0 5994
47
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 106133-20-4 129211
48
Nifedipine Approved Phase 4,Phase 3,Phase 2,Phase 1 21829-25-4 4485
49
Propantheline Approved Phase 4,Phase 1 298-50-0 4934
50
Insulin Glargine Approved Phase 4,Phase 3 160337-95-1

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
2 Cranberry for the Prevention of Urinary Tract Infections Unknown status NCT02454309 Phase 4
3 Effects of Antibiotic Prophylaxis on Recurrent UTI in Children Unknown status NCT02357758 Phase 4 Antibiotic Prophylaxis
4 Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism Unknown status NCT02311010 Phase 4 Advagraf
5 The Efficacy of Solifenacin Succinate as Adjuvant Therapy for Urinary Tract Infection in Females Unknown status NCT02094703 Phase 4 Levofloxacin;Solifenacin succinate;Placebo (for Solifenacin succinate)
6 Gentamicin Bladder Instillation Trial Unknown status NCT01884467 Phase 4 Gentamicin;Placebo
7 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
8 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
9 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
10 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus
11 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
12 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
13 Low Dose Estriol With Lactobacilli Treatment for Preventing Recurrent Urinary Tract Infection in Postmenopausal Women Unknown status NCT00900653 Phase 4 Gynoflor E (low dose estriol with lactobacillus)
14 Safe Renal Function In Long Term Heart Transplanted Patients Unknown status NCT00505102 Phase 4 Everolimus
15 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
16 Renal Function Optimization With Mycophenolate Mofetil (MMF) Immunosuppressor Regimes (ALHAMBRA) Unknown status NCT00290069 Phase 4 Tacrolimus;Rapamycin
17 Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation Unknown status NCT00246129 Phase 4 Alemtuzumab;Daclizumab
18 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
19 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
20 Evaluation of the Effectiveness of Antibiotic Prophylaxis in Children With a Previous Urinary Tract Infection Unknown status NCT00156546 Phase 4 antibiotic to reduce the recurrence of infection
21 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
22 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
23 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
24 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
25 Piperacillin Sodium and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection Unknown status NCT01897831 Phase 4 xin te mie
26 Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) for Treatment of Respiratory and Urinary System Infection Unknown status NCT01760109 Phase 4 Piperacillin Sodium and Sulbactam Sodium
27 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
28 BIP Foley in Prevention of CAUTI at Rehab Station Unknown status NCT02808000 Phase 4
29 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
30 Minimizing Contrast Utilization With IVUS Guidance in Coronary Angioplasty to Avoid Acute Nephropathy Unknown status NCT02743156 Phase 4
31 A New Anticoagulation Method Using Dalteparin in Quotidian and Nocturnal Home Hemodialysis Patients Unknown status NCT02607111 Phase 4 Dalteparin
32 Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients Unknown status NCT01351636 Phase 4 Arotinolol Hydrochloride;Non arotinolol group
33 Thymoglobulin Induction Therapy in Kidney Transplantation (6mg/kg vs 4mg/kg) Unknown status NCT02447822 Phase 4 Thymoglobulin
34 Efficacy of Combined Intravesical Therapy With Hyaluronic Acid and Chondroitin Sulphate in the Treatment of Recurrent Cystitis Refractory to Escherichia Coli Extract Unknown status NCT02366676 Phase 4 IALURIL
35 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
36 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
37 Renal Effects of Meditarranean Diet and Low-protein Diet With Ketoacids on Physiological Intestinal Mibrobiota in CKD Unknown status NCT02302287 Phase 4
38 A Prospective Study Comparing the Success Rate of Injection of (DefluxR) Versus (VantrisR) for VUR in Children Unknown status NCT02271035 Phase 4 Deflux;Vantris
39 Clinical Trial to Compare Effectiveness of Diuretics in Hemodialysis Patients With Residual Renal Function Unknown status NCT01977430 Phase 4 Hydrochlorothiazide and furosemide
40 Pilot Study Evaluating Doxercalciferol Replacement Therapy in Kidney Transplant Recipients Unknown status NCT00889629 Phase 4 Doxercalciferol;placebo
41 Effect of 3g Versus 2 g MMF in Combination With Tacrolimus on Progression of Renal Allograft Interstitial Fibrosis Unknown status NCT01860183 Phase 4 Mycophenolate mofetil
42 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
43 More Frequent Dialysis (>3 Treatments Per Week) Unknown status NCT00575497 Phase 4
44 Inspiratory Muscle Training in Patients With End Stage Renal Failure Unknown status NCT01347775 Phase 4
45 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
46 Effects of Spironolactone in Dialysis Unknown status NCT01128101 Phase 4 Spironolactone
47 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
48 Effect of Hydration With Sodium Bicarbonate for Long-Term Clinical Outcomes in Patients With Chronic Kidney Disease Undergoing an Emergent Coronary Procedure Unknown status NCT00716001 Phase 4 N-acetylcysteine
49 The Pharmacogenetics of Optimal Warfarin Therapy in Chinese Patients After Heart Valve Replacement. Unknown status NCT02710747 Phase 4
50 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4

Search NIH Clinical Center for Urinary System Disease

Sources

Genetic Tests for Urinary System Disease

About this section

Genetic tests related to Urinary System Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Urinary System 29
Sources

Anatomical Context for Urinary System Disease

About this section

MalaCards organs/tissues related to Urinary System Disease:

41
Kidney, Endothelial, Skin, Liver, Bone, Heart, Pancreas

The Foundational Model of Anatomy Ontology organs/tissues related to Urinary System Disease:

19
Kidney
Sources

Publications for Urinary System Disease

About this section

Articles related to Urinary System Disease:

# Title Authors Year
1
Epidemiologic approach for early detection and control of renal and urinary tract diseases in rural populations. ( 17580586 )
2007
2
N-Glycans carried by Tamm-Horsfall glycoprotein have a crucial role in the defense against urinary tract diseases. ( 16622944 )
2005
3
Expression of platelet-derived endothelial cell growth factor and its potential role in up-regulation of angiogenesis in scarred kidneys secondary to urinary tract diseases. ( 10550316 )
1999
4
Urinary beta-HCG in benign and malignant urinary tract diseases. ( 7542189 )
1995
5
Natural history of peptic ulcer disease in Poland. Part X. Peptic ulcer disease and urinary tract diseases and diabetes. ( 2132430 )
1990
6
A population study on renal and urinary tract diseases. 3. A diagnostic dilemma: occurrence of pyuria and bacteriuria in conventional and clean-voided midstream specimens and suprapublic urine. ( 4589795 )
1973
Sources

Variations for Urinary System Disease

About this section
Sources

Expression for Urinary System Disease

About this section
Search GEO for disease gene expression data for Urinary System Disease.
Sources

Pathways for Urinary System Disease

About this section

Pathways related to Urinary System Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Primary Focal Segmental Glomerulosclerosis FSGS 1
10.67 NPHS1 NPHS2 WT1
2
Osteoblast Signaling 1
10.1 FGF23 PTH
Sources

GO Terms for Urinary System Disease

About this section

Cellular components related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.85 ACE ALB B2M CST3 KLK3 LCN2
2 extracellular space GO:0005615 9.7 ACE ALB B2M CRP CST3 EPO
3 endoplasmic reticulum lumen GO:0005788 9.62 ALB B2M CST3 FGF23
4 extracellular region GO:0005576 9.44 ACE ALB B2M CRP CST3 EPO
5 slit diaphragm GO:0036057 9.26 NPHS1 NPHS2

Biological processes related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 amyloid-beta metabolic process GO:0050435 9.46 ACE REN
2 response to molecule of bacterial origin GO:0002237 9.43 B2M TLR9
3 angiotensin maturation GO:0002003 9.4 ACE REN
4 glomerular basement membrane development GO:0032836 9.37 NPHS1 WT1
5 excretion GO:0007588 9.33 NPHS1 NPHS2 UMOD
6 metanephric mesenchyme development GO:0072075 9.32 SIX1 WT1
7 phosphate ion homeostasis GO:0055062 9.26 FGF23 PTH
8 kidney development GO:0001822 9.26 ACE REN SIX1 WT1
9 cellular protein metabolic process GO:0044267 9.02 ALB B2M CST3 FGF23 KLK3

Molecular functions related to Urinary System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 8.8 ACE KLK3 REN
Sources

Sources for Urinary System Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....